Navigation Links
Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes

OAKLAND, Calif., Oct. 12 /PRNewswire/ -- Cardio-metabolic risk factors such as high blood sugar and insulin, and low high density lipoprotein cholesterol that are present before pregnancy, predict whether a woman will develop diabetes during a future pregnancy, according to a Kaiser Permanente study in the current issue of the American Journal of Epidemiology.

The study suggests that metabolic screening of all women before pregnancy, particularly overweight women, could help identify those more likely to develop gestational diabetes mellitus, known as GDM, in a subsequent pregnancy and help them take preventive steps prior to conception.

Women who develop GDM during pregnancy are more likely to develop Type 2 diabetes after pregnancy, previous research has shown. GDM is defined as glucose intolerance that typically occurs during the second or third trimester and causes complications in as much as 7 percent of pregnancies in the United States. It can lead to early delivery and Cesarean sections and increases the baby's risk of developing diabetes, obesity and metabolic disease later in life.

The study is among the first to measure cardio-metabolic risk factors before pregnancy in women 18-30 years of age without diabetes who later became pregnant and reported whether they had developed GDM. The research provides evidence to support pre-conception care for healthy pregnancies as noted in a 2006 report by the U.S. Centers for Disease Control and Prevention. That report suggested that risk factors for adverse outcomes among women and infants can be identified prior to conception and are characterized by the need to start, and sometimes finish, interventions before conception occurs.

"Our study suggests that women may benefit from a focus on care before conception that would encourage screening for metabolic abnormalities before pregnancy, rather than only during pregnancy. Because weight loss is not advised, and the medication and behavioral treatment options are more limited during pregnancy, the time to prevent gestational diabetes is before pregnancy begins," said study lead investigator Erica P. Gunderson, PhD, an epidemiologist and research scientist at the Kaiser Permanente Division of Research in Oakland, Calif. "Screening and treatment of metabolic risk factors before pregnancy to prevent GDM may help reduce its lasting adverse health effects on children, by possibly improving the uterine environment," she added.

Researchers studied 1,164 women without diabetes before pregnancy who delivered 1,809 live births during the course of five consecutive exams from 1985-2006 as part of a Coronary Artery Risk Development in Young Adults study. Participant characteristics – including  lifestyle, socio-demographic, medical conditions, medication use, family history of diabetes, pregnancies and births and GDM status, as well as clinical assessments, body measurements and blood specimens – were  obtained at baseline. Follow-up exams used standardized research methodologies, including self- and interviewer-administered questionnaires.

Impaired fasting glucose, elevated fasting insulin and low HDL-cholesterol before pregnancy were associated with higher risk of GDM. Of the 1,809 live births studied, 154 (8.5 percent) involved a GDM pregnancy.

Among overweight women, 26.7 percent with one or more cardio-metabolic risk factors before pregnancy developed gestational diabetes versus 7.4 percent who did not have cardio-metabolic risk factors.

Although obesity and belly fat are antecedents to insulin resistance, pre-pregnancy obesity was not independently predictive of GDM after taking into account cardio-metabolic risk factors. Researchers also found no association between pre-pregnancy blood pressure or hypertension and risk of GDM, possibly due to the low prevalence of these conditions in healthy women of reproductive age.

This study is part of ongoing research at Kaiser Permanente to understand, prevent and treat gestational diabetes. Recent Kaiser Permanente research includes:

Co-authors of the current study include Charles P. Quesenberry, PhD; Juanran Feng, MS, and Stephen Sidney, MD, MPH, all from the Kaiser Permanente Division of Research; David R. Jacobs, PhD, the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota; and Cora E. Lewis, MD, MSPH, Division of Preventive Medicine, University of Alabama at Birmingham.

The study was funded by the National Institutes of Health, the National Heart, Lung and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases and the American Diabetes Association.

About Kaiser Permanente Division of Research

The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and the society at large. It seeks to understand the determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Currently, DOR's 500-plus staff is working on more than 250 epidemiological and health services research projects. For more information, visit

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 8.6 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, visit

SOURCE Kaiser Permanente
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
4. NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease
5. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
6. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
7. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
8. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
11. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):